Muscular Dystrophy is an X-linked
recessive genetic condition that causes muscular deterioration. It can,
however, be inherited from parents or created by a novel mutation. Although
there are different therapy and medicines to regulate DMD, there is still no
cure for the disease.
The introduction of novel medications
and therapies, disease-modifying therapies, strong backing from various firms
for drug research, and support from patient advocacy groups on the regulatory
approval process are all major driving drivers in the worldwide
muscular dystrophy treatment market. Furthermore, mutation-specific
medicines are expected to be a big breakthrough in the treatment of muscular
dystrophy.
The FDA's specific recommendation is projected
to dominate the worldwide market in North America
North America, Latin America, Europe,
Asia-Pacific, and the Middle East and Africa are the regions where the
worldwide muscular dystrophy therapy market is segmented. In 2007, the Centers
for Disease Control and Prevention estimated that 349 out of 2.37 million males
aged 5 to 24 years in the United States had duchenne muscular dystrophy or
becker muscular dystrophy. Due to the lack of licenced pharmacological
medicines indicated to treat muscular dystrophy, rising prevalence of the
condition, and increased research and development for creating effective
pharmaceuticals, North America is likely to lead the worldwide muscular
dystrophy treatment market. With rising public awareness and increased research
activity, Europe is likely to increase its market share during the forecast
period.
The introduction of effective corticosteroids
is expected to increase market demand
Santhera Pharmaceuticals, PTC
Therapeutics, BioMarin Pharmaceutical, Sarepta Therapeutics, and Eli Lilly are
among the leading companies in the global muscular dystrophy therapy market.
Emflaza, an oral corticosteroid approved and launched in 2017, has been
demonstrated to be highly successful in helping patients develop strength and
walk again. Acceleron Pharma, Capricor Therapeutics, Bristol-Myers Squibb,
Lexicon Pharmaceuticals, and Pfizer are among the other providers.
Comments
Post a Comment